This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally
Nuvalent develops targeted therapies for drug-resistant cancers, advancing clinical-stage candidates in precision oncology.
📰 Original Source
Read full article at Fool →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.